Stock Quote

JPMorgan downgrades Moderna on valuation concerns after 380% rally this year

Moderna skyrocketed 384% this year as investors bet it will become one of the first drugmakers to develop a viable coronavirus vaccine.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.